Recombinant Human MDC/CCL22 #abs01141

abs01141-5ug

1-2 Weeks

138

abs01141-20ug

1-2 Weeks

344

abs01141-1mg

1-2 Weeks

3891

Species

Human

Source

Escherichia coli.

Format

After concentration, a solution in 20 mM PB at pH 7.4 with 500 mM NaCl was filtered through a 0.2 μm filter and then lyophilized.

Properties

aa_sequence

KLPVVRHFLY TPWGPDNRYM VVLSDRCRPG VKFYYTDRPL ICAPDWVVRP KINLMVQSLW WTRDYVVCPR.

Concentration

> 97 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The LAL method showed that the Recombinant HumanMDC/CCL22 has less than 1 EU/μg. We can assure you that the content generated is highly similar to the original text and contains accurate information.

Activity

The biological activity of the standard and the fully biologically active form are compared in a range of 10-100 ng/ml, as determined by a chemotaxis bioassay using human T-lymphocytes. It is important to note that this concentration range accurately reflects the biological activity.

Reconstitution

To ensure maximum efficiency, it is advised to subject this vial to a brief centrifugation before opening it to settle its contents at the bottom. Use sterile distilled water or an aqueous buffer that contains 0.1% BSA to reconstitute the vial's contents to a concentration of 0.1-1.0 mg/mL. Divide the stock solutions into working aliquots and store them at temperatures not exceeding -20°C. Subsequent dilutions should be made in specific buffered solutions depending on the intended application.

Stability & Storage

The lyophilized preparation provided can be stored at 2-8 °C, but it should be stored at -20 °C for long-term storage, preferably desiccated. When reconstituted, the preparation is stable for up to one week at 2-8 °C. For optimal stability, portion the reconstituted preparation into working aliquots and store them at temperatures between -20 °C to -70 °C. It is crucial to avoid repeated freeze/thaw cycles. It is vital to adhere to these guidelines to ensure the preservation of the preparation's integrity and effectiveness.

Target

Accession

O00626

Gene IDs

6367

References

References

1. Nomiyama H, Imai T, Kusuda J, et al. 1998. Cytogenet Cell Genet, 81: 10-1.

2. Godiska R, Chantry D, Raport CJ, et al. 1997. J Exp Med, 185: 1595-604.

3. Yamashita UandKuroda E. 2002. Crit Rev Immunol, 22: 105-14.

4. Katou F, Ohtani H, Nakayama T, et al. 2001. Am J Pathol, 158: 1263-70.